

# Contents

<b>Abbreviations and acronyms</b>	vii
<b>1. Introduction</b>	1
<b>2. The burden of rabies</b>	1
2.1 Methods for estimating the burden of rabies	2
2.2 Estimated global human burden of rabies	3
2.3 Global burden of rabies	6
2.4 References	8
<b>3. Classification of lyssaviruses</b>	10
3.1 Distinguishing features of lyssaviruses	10
3.2 Criteria for differentiating lyssaviruses	10
3.3 Present structure of the <i>Lyssavirus</i> genus	11
3.4 References	15
<b>4. Pathogenesis</b>	17
4.1 References	19
<b>5. Diagnosis</b>	21
5.1 Standard case definitions for rabies	21
5.2 Clinical diagnosis	22
5.3 Biosafety, sampling and specimen transport for laboratory diagnosis	23
5.4 Laboratory techniques for post-mortem diagnosis of rabies in humans and animals	25
5.5 Techniques for ante-mortem diagnosis of rabies in humans	32
5.6 Measuring antibody response to rabies vaccination in humans	34
5.7 Measuring antibody response to rabies vaccination in animals	35
5.8 Virus identification with molecular techniques: epidemiological considerations	35
5.9 References	36
<b>6. Management of patients before and after death</b>	39
6.1 Management of patients with rabies	39
6.2 Palliative management of patients with rabies	41
6.3 Recommendations for health care personnel and family members of patients with rabies	42
6.4 Survivors of rabies and "aggressive" treatment protocols	43
6.5 Management of the bodies of patients who have died of rabies	44
6.6 Transmission via organ transplantation	45
6.7 References	45

<b>7. Vaccines and rabies immunoglobulins for humans</b>	47	<b>11. Surveillance of rabies</b>	111
7.1 Vaccine types	47	11.1 Surveillance systems	112
7.2 WHO prequalification of human rabies vaccines	49	11.2 Global reporting	117
7.3 Requirements for human rabies vaccines	49	11.3 References	118
7.4 Routes of vaccine administration	50	<b>12. Reaching zero human deaths from rabies</b>	120
7.5 Adverse events after active immunization	51	12.1 Core elements of validation, verification and rabies-freedom	122
7.6 Duration of immunity	52	12.2 Validation of zero human deaths from rabies	123
7.7 Failure of rabies vaccine and of full post-exposure prophylaxis	52	12.3 Verification of interruption of rabies transmission	124
7.8 Rabies immunoglobulins	52	12.4 References	124
7.9 References	54	<b>13. Global and regional activities on rabies</b>	125
<b>8. Prevention of human rabies</b>	57	13.1 WHO global and regional activities	125
8.1 General considerations	57	13.2 Examples of activities by partners	129
8.2 Pre-exposure prophylaxis	58	13.3 References	134
8.3 Post-exposure prophylaxis	60	<b>14. Research</b>	137
8.4 Use of rabies immunoglobulins for passive immunization	68	14.1 Improve programmatic delivery of rabies interventions	137
8.5 Contraindications and precautions to be taken in post-exposure prophylaxis	69	14.2 Improve the quality and availability of data on rabies	139
8.6 Supply limitations	70	14.3 Evidence and new tools to improve the prevention and management of rabies	139
8.7 Travel to rabies-affected countries and areas and indications for pre-exposure prophylaxis	70	14.4 References	140
8.8 Education to prevent bites	72	<b>15. Concluding remarks</b>	141
8.9 References	72	<b>16. Acknowledgements</b>	141
<b>9. Prevention and control of rabies in dogs</b>	78	<b>Annexes</b>	
9.1 Case definition of animal rabies	78	<b>Annex 1</b>	
9.2 Methods for controlling dog rabies	79	List of participants	
9.3 International movement of animals	89	<b>Annex 2</b>	
9.4 Humane dog population management	90	Record form for cases of possible exposure to rabies	
9.5 Vaccination versus sterilization	90	<b>Annex 3</b>	
9.6 National programmes for dog rabies control: lessons from the field	91	Human rabies vaccines and producers worldwide, as of August 2017	
9.7 References	92	<b>Annex 4</b>	
<b>10. Prevention and control of rabies in wild animals</b>	96	Four steps for replacing nerve tissue vaccine by modern rabies vaccines produced on cell culture or embryonated eggs	
10.1 Epidemiology and ecology of rabies in carnivore species	96	<b>Annex 5</b>	
10.2 Epidemiology and ecology of rabies in bats	98	Rabies immunoglobulin (RIG) products and producers worldwide, as of August 2017	
10.3 Rabies in rodents	101		
10.4 Wildlife species of special concern	101		
10.5 Elimination of rabies in wild carnivores	102		
10.6 Control of rabies in bats	106		
10.7 Other public health measures	107		
10.8 References	107		

<b>Annex 6</b>		
	Technique for intradermal administration of rabies vaccine and precautions to be taken	153
<b>Annex 7</b>		
	Sites for intramuscular and intradermal administration of human rabies vaccine	155
<b>Annex 8</b>		
	Recommended post-exposure prophylaxis according to type of exposure	156
<b>Annex 9</b>		
	Suggested rabies vaccination certificates for humans	157
<b>Annex 10</b>		
	Currently available oral rabies vaccine products	159
<b>Annex 11</b>		
	Verbal autopsy questionnaire	160
<b>Annex 12</b>		
	Animal bite investigation form	171
<b>Annex 13</b>		
	WHO data collection template	174
<b>Annex 14</b>		
	Template dossier for validation and verification	175
<b>Annex 15</b>		
	WHO collaborating centres on rabies, neurovirology, viruses, viral zoonoses and zoonosis control	182